acute leukemia

Objective. To study risk factors, etiology, clinical signs and treatment outcomes of invasive aspergillosis (IA) and mucormycosis combination (IAM) in children. Materials and Methods. A retrospective review of Saint-Petersburg register (1998–2021) of patients with IA was done and children with IAM were included. EORTC/MSGERG 2019 criteria were used for diagnosing and treatment results evaluation of invasive mycosis. We presented a clinical case of IAM in a child with acute lymphoblastic leukemia relapse.

Objective. To assess the incidence rate, risk factors and treatment outcomes of mucormycosis in children with hematological malignancies in the large tertiary hematology/oncology center. Materials and Methods. A total of 16 children (9 males/7 females) with mucormycosis were enrolled in a single-center, retrospective study over the period of 2012–2018. All patients had an underlying diagnosis of acute leukemia. Mucormycosis was diagnosed at the different timepoints after chemotherapy (CT) or hematopoietic stem cell transplantation (HSCT) in 15 cases and before CT in 1 case.